New targeted drug trial launches for Hard-to-Treat cancers
NCT ID NCT07383506
Summary
This early-stage study is testing a new targeted drug called CGT6297 in adults with advanced solid tumors that have a specific genetic change called a PIK3CA mutation. The main goals are to find a safe dose and see if the drug shows early signs of helping to shrink tumors. The study will include people with cancers like endometrial cancer and certain types of breast cancer who have already tried standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Austin
Austin, Texas, 78758, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.